← back to search

Sara Pressel

New York University · US
Area of research
Cardiology and Cardiovascular Medicine · Surgery
Research interest
Research focused on Transcranial Doppler and Chlorthalidone, with related work in Fetal hemoglobin, Clinical endpoint, Hydroxycarbamide. Notable publications include 'Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to...', 'Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease', and 'Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults'.
h-index
citations
1,155
works
8
NIH funding
primary concept
email

Recent publications

Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults
JAMA Internal Medicine 2017cited by 185position: middledoi
Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults
JAMA Internal Medicine 2016cited by 69position: middledoi
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
The Lancet 2015cited by 509position: middledoi
Effects of hydroxyurea treatment for patients with hemoglobin <scp>SC</scp> disease
American Journal of Hematology 2015cited by 79position: middledoi
TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia
Blood 2015cited by 17position: middledoi
Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease
Hypertension 2014cited by 226position: middledoi
Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT
Journal of Hypertension 2014cited by 52position: middledoi
Treatment resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Journal of the American Society of Hypertension 2014cited by 18position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Barry R. Davis · The University of Texas Health Science Center at Houston6 papers (2014–2017)William C. Cushman · University of Tennessee Health Science Center3 papers (2014–2016)Paul K. Whelton · Shanghai Institute of Hypertension3 papers (2014–2016)Joshua I. Barzilay · Kaiser Permanente2 papers (2014–2016)John B. Kostis · Rutgers, The State University of New Jersey2 papers (2014–2014)Mahboob Rahman · University School2 papers (2014–2014)Paula T. Einhorn · Tulane University2 papers (2014–2016)David A. Calhoun · University of Alabama at Birmingham2 papers (2014–2014)Sripal Bangalore · Hinge Health2 papers (2014–2014)Paul Muntner · Diagnostics for the Real World (United States)2 papers (2014–2014)Henry R. Black · New York University2 papers (2014–2014) · 1 papers (2014–2014)Carla W. Roberts · University of South Carolina1 papers (2015–2015)Kathryn L. Hassell · Children's Hospital Colorado1 papers (2015–2015)Suzanne Oparil · University of Alabama at Birmingham1 papers (2016–2016)Lori Luchtman‐Jones · University of Illinois Chicago1 papers (2015–2015)Efrain Reisin · Tulane University1 papers (2014–2014)Lee Hilliard · University of Alabama at Birmingham1 papers (2015–2015)Hannah Pervin · The University of Texas Health Science Center at Houston1 papers (2017–2017)Richard A. Dart · University of Arizona1 papers (2014–2014)